[1]
|
Hosen, M.R., Goody, P.R., Zietzer, A., et al. (2020) MicroRNAs as Master Regulators of Atherosclerosis: From Path-ogenesis to Novel Therapeutic Options. Antioxidants & Redox Signaling, 33, 621-644.
https://doi.org/10.1089/ars.2020.8107
|
[2]
|
Zhu, Y., Xian, X., Wang, Z., et al. (2018) Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules, 8, Article No. 80. https://doi.org/10.3390/biom8030080
|
[3]
|
Libby, P., Buring, J.E., Badimon, L., et al. (2019) Atherosclerosis. Nature Reviews Disease Primers, 5, Article No. 56.
https://doi.org/10.1038/s41572-019-0106-z
|
[4]
|
Xu, S., Pelisek, J. and Jin, Z.G. (2018) Atherosclerosis Is an Epigenetic Disease. Trends in Endocrinology and Metabolism, 29, 739-742. https://doi.org/10.1016/j.tem.2018.04.007
|
[5]
|
Veseli, B.E., Perrotta, P., Meyer, G., et al. (2017) Animal Models of Atherosclerosis. European Journal of Pharmacology, 816, 3-13. https://doi.org/10.1016/j.ejphar.2017.05.010
|
[6]
|
Ye, Z., Lu, Y. and Wu, T. (2020) The Impact of ATP-Binding Cassette Transporters on Metabolic Diseases. Nutrition & Metabolism, 17, Article No. 61. https://doi.org/10.1186/s12986-020-00478-4
|
[7]
|
Ouimet, M., Barrett, T.J. and Fisher, E.A. (2019) HDL and Reverse Cholesterol Transport: Basic Mechanisms and Their Roles in Vascular Health and Disease. Circulation Research, 124, 1505-1518.
https://doi.org/10.1161/CIRCRESAHA.119.312617
|
[8]
|
张静, 赵外荣, 施雯婷, 周忠焱, 陈昕琳. 中医药调控平滑肌细胞增殖抑制动脉粥样硬化的研究进展[J]. 中华中医药杂志, 2021, 36(9): 5429-5432.
|
[9]
|
Xavier, B.M, Jennings, W.J., Zein, A.A., et al. (2019) 631 Structural Snapshot of the Cholesterol-Transport ABC Proteins. Biochem-istry and Cell Biology, 97, 224-233.
|
[10]
|
Tan, L., Liu, L., Jiang, Z., et al. (2018) Inhibition of MicroRNA-17-5p Re-duces the Inflammation and Lipid Accumulation, and Up-Regulates ATP-Binding Cassette transportera1 in Athero-sclerosis. Journal of Pharmacological Sciences, 139, 280-288. https://doi.org/10.1016/j.jphs.2018.11.012
|
[11]
|
Srikant, S. (2020) Evolutionary History of ATP-Binding Cassette Proteins. FEBS Letters, 594, 3882-3897.
https://doi.org/10.1002/1873-3468.13985
|
[12]
|
Yin, Q., Chang, H., Shen, Q., et al. (2021) Photobiomodulation Therapy Promotes the ATP-Binding Cassette Transporter A1-Dependent Cholesterol Efflux in Macrophage to Ame-liorate Atherosclerosis. Journal of Cellular and Molecular Medicine, 25, 5238-5249. https://doi.org/10.1111/jcmm.16531
|
[13]
|
李佳珊, 关秀茹. ABCA1: 调控胆固醇逆向转运与炎症激活之间关系的研究新进展[J]. 心血管病学进展, 2021, 42(7): 649-652.
|
[14]
|
张瑜, 闫长宝, 李悦, 等. 中医药调节动脉粥样硬化的细胞自噬研究进展[J]. 中国现代药物应用, 2021, 15(16): 232-234.
|
[15]
|
李帅帅, 于红红, 田维毅. 中医药防治动脉粥样硬化炎症反应相关信号通路研究进展[J]. 中国实验方剂学杂志, 2020, 26(23): 180-186.
|
[16]
|
李西云, 郭迎树. 中医药治疗动脉粥样硬化研究进展[J]. 河南医学研究, 2021, 30(27): 5180-5183.
|
[17]
|
王丹丹, 封锐, 师帅, 魏娜敏, 胡元会. 痰瘀同治抗动脉粥样硬化机制的研究进展[J]. 中国医药导报, 2021, 18(30): 53-55.
|
[18]
|
施乐, 赵聪娜. 动脉粥样硬化中医药治疗的研究进展[J]. 现代诊断与治疗, 2021, 32(10): 1528-1530.
|
[19]
|
李英, 龚宝莹, 朱建华, 等. 国医大师朱良春从痰瘀论治颈动脉不稳定斑块的学术经验[J]. 中国实验方剂学杂志, 2021, 27(23): 195-200.
|
[20]
|
戴缙. 论中药归经、引经理论在组方配伍中的应用研究[D]: [博士学位论文]. 哈尔滨: 黑龙江中医药大学, 2018.
|
[21]
|
李帅帅, 于红红, 田维毅. 四妙勇安汤及配伍成分抗动脉粥样硬化作用机制研究进展[J]. 中华中医药学刊, 2021, 39(11): 125-129.
|
[22]
|
吕昕儒, 魏伟, 王夏蕾, 等. 基于胆固醇逆转运探讨泽泻白术配伍改善ApoE−/−小鼠动脉粥样硬化的作用[J]. 中国动脉硬化杂志, 2021, 29(4): 286-294.
|
[23]
|
Zheng, S.S., Huang, H., Li, Y.Z., et al. (2021) Yin-Xing-Tong-Mai Decoction Attenuates Atherosclerosis via Activating PPARγ-LXRα-ABCA1/ABCG1 Pathway. Pharmacological Research, 169, Article ID: 105639.
https://doi.org/10.1016/j.phrs.2021.105639
|
[24]
|
Lu, L., Qin, Y., Zhang, X., et al. (2019) Shexiang Baoxin Pill Alleviates the Atherosclerotic Lesions in Mice via Improving Inflammation Response and Inhibiting Lipid Accumulation in the Arterial Wall. Mediators of Inflammation, 2019, Article ID: 6710759. https://doi.org/10.1155/2019/6710759
|
[25]
|
许丽婷, 徐彬人, 盛蒙, 吴琼, 王文佳, 田维毅, 俞琦. 黄连解毒汤含药血清对泡沫细胞ABCA1表达与胆固醇含量的影响[J]. 中国民族民间医药, 2020, 29(6): 10-13.
|
[26]
|
马星雨. 小陷胸汤对RAW264.7源泡沫细胞ABCA1/G1表达和胆固醇流出的影响[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2020.
|
[27]
|
翟意. 健脾化浊法通过调节ApoE−/−小鼠胆固酵代谢抗动脉粥样硬化的实验探究[D]: [硕士学位论文]. 南京: 南京中医药大学, 2020.
|
[28]
|
Cui, Y., Liu, J., Huang, C., et al. (2019) Moxibustion at CV4 Al-leviates Atherosclerotic Lesions through Activation of the LXRα/ABCA1 Pathway in Apolipoprotein-E-Deficient Mice. Acupuncture in Medicine, 37, 237-243.
https://doi.org/10.1136/acupmed-2016-011317
|
[29]
|
鹿琦, 王潞, 李双双, 姜敏, 俞淑文. 中药单体化合物诱导巨噬细胞表型极化的作用机制研究进展[J]. 中国药房, 2020, 31(15): 1915-1920.
|
[30]
|
刘文杰. 余甘子防治动脉粥样硬化活性成分及机制研究[D]: [硕士学位论文]. 济南: 齐鲁工业大学, 2021.
https://doi.org/10.27278/d.cnki.gsdqc.2021.000349
|
[31]
|
Gao, H., Li, L., Li, L., et al. (2016) Danshensu Promotes Cholesterol Efflux in RAW264.7 Macrophages. Lipids, 51, 1083-1092. https://doi.org/10.1007/s11745-016-4178-1
|
[32]
|
Qian, Y., Xia, L., Wei, L., et al. (2021) Artesunate Attenuates foam Cell Formation by Enhancing Cholesterol Efflux. Annals of Translational Medicine, 9, Article No. 1379. https://doi.org/10.21037/atm-21-3551
|
[33]
|
农微, 陆宏浩, 韦金锐, 陈柏承, 覃子洺, 许思敏, 卫智权. 金花茶叶醇提物通过调节胆固醇逆向转运关键蛋白的表达抑制动脉粥样硬化[J]. 中国医院药学杂志, 2021, 41(24): 2519-2525.
|
[34]
|
陈琼, 黄水清. 黄芪总皂苷、当归挥发油对动脉粥样硬化ApoE−/−小鼠脂质代谢的影响[J]. 中药新药与临床药理, 2021, 32(6): 791-798.
|
[35]
|
汪瑜翔, 姜爽, 石雅宁, 等. 雷公藤红素通过激活LXRα/ABCA1通路和细胞自噬抑制巨噬细胞脂质蓄积[J]. 生物化学与生物物理进展, 2021, 48(7): 836-845.
|
[36]
|
王帅, 王凤荣. 姜黄素对泡沫细胞胆固醇流出及SREBP1、ABCA1表达的影响[J]. 时珍国医国药, 2020, 31(7): 1580-1583.
|